Literature DB >> 10049754

Mechanism of Ret activation by a mutation at aspartic acid 631 identified in sporadic pheochromocytoma.

N Asai1, T Iwashita, H Murakami, H Takanari, K Ohmori, M Ichihara, M Takahashi.   

Abstract

Mutations at aspartic acid 631 in Ret were reported in sporadic pheochromocytoma and medullary thyroid carcinoma. We replaced this aspartic acid with four other amino acids including tyrosine, glycine, asparagine, and alanine and investigated the transforming activity of these mutant cDNAs. Among them, RET cDNA with a mutation of aspartic acid to tyrosine (D631Y) that was reported in sporadic pheochromocytoma showed high transforming activity. The D631Y mutation activated Ret by inducing its disulfide-linked dimerization in the transfectant as observed for multiple endocrine neoplasia (MEN) 2A mutations at cysteine 609, 611, 618, 620, 630, or 634. Further mutation analysis suggested that cysteine 630 or 634 could be involved in the disulfide-linked Ret dimerization induced by the D631Y mutation. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10049754     DOI: 10.1006/bbrc.1999.0237

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

Review 1.  Neurotrophic factors and their receptors in axonal regeneration and functional recovery after peripheral nerve injury.

Authors:  J Gordon Boyd; Tessa Gordon
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

Review 2.  Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.

Authors:  Alexander Drilon; Zishuo I Hu; Gillianne G Y Lai; Daniel S W Tan
Journal:  Nat Rev Clin Oncol       Date:  2017-11-14       Impact factor: 66.675

3.  Clinical features and signaling effects of RET D631Y variant multiple endocrine neoplasia type 2 (MEN2).

Authors:  Ji-Young Lee; Su Yeon Kim; Kwan Hoon Jo; Eun Yeong Mo; Eun Sook Kim; Hye Soo Kim; Je Ho Han; Sung-Dae Moon
Journal:  Korean J Intern Med       Date:  2021-12-15       Impact factor: 3.165

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.